BCAX
Bicara Therapeutics Inc. Common Stock
$21.68
+0.84
(+4.03%)
Mkt Cap
1.19B
Volume
333,148
52W Range
8.48-24.25
Sector
Healthcare
Beta
-0.56
EPS (TTM)
-2.78
P/E Ratio
-6.67
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Net Income | (137.95M) | (68.00M) | (51.98M) | (37.84M) |
| EPS | -2.52 | -1.25 | -1.00 | -0.73 |
| Free Cash Flow | (107.11M) | (74.82M) | (46.21M) | (32.27M) |
| FCF / Share | -1.96 | -1.37 | -0.89 | -0.62 |
| Operating CF | (106.83M) | (74.75M) | (45.63M) | (32.08M) |
| Total Assets | 430.99M | 569.20M | 233.98M | 6.70M |
| Total Debt | 1.71M | 738,000 | 657,000 | 0 |
| Cash & Equiv | 96.69M | 489.71M | 230.44M | 4.16M |
| Book Value | 401.45M | 491.88M | 218.51M | (17.28M) |
| Return on Equity | -0.34 | -0.14 | -0.24 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.21M) | (37.39M) | (36.33M) | (27.39M) | (36.85M) | (20.96M) | (17.48M) | (17.05M) | (12.51M) | (12.44M) | (22.84M) | (8.35M) |
| EPS | -0.93 | -0.68 | -0.67 | -0.50 | -0.68 | -0.38 | -0.32 | -0.27 | -0.27 | -0.23 | -0.42 | -0.15 |
| Free Cash Flow | (37.57M) | (24.12M) | (29.29M) | (25.59M) | (28.11M) | (30.07M) | (17.23M) | (12.93M) | (14.59M) | (8.47M) | (10.68M) | (13.53M) |
| FCF / Share | -0.62 | -0.44 | -0.54 | -0.47 | -0.52 | -0.55 | -0.32 | -0.24 | -0.27 | -0.16 | -0.20 | -0.25 |
| Operating CF | (37.51M) | (23.89M) | (29.25M) | (25.59M) | (28.11M) | (30.03M) | (17.22M) | (12.91M) | (14.59M) | (8.04M) | (10.53M) | (13.53M) |
| Total Assets | 553.60M | 430.99M | 424.69M | 453.59M | 478.08M | 569.20M | 524.17M | 208.78M | 208.78M | 233.98M | N/A | N/A |
| Total Debt | 1.44M | 1.71M | 1.98M | 2.24M | 591,000 | 738,000 | 445,000 | 517,000 | 517,000 | 657,000 | N/A | N/A |
| Cash & Equiv | 323.46M | 96.69M | 171.67M | 436.61M | 462.06M | 489.71M | 520.76M | 203.85M | 203.85M | 230.44M | N/A | N/A |
| Book Value | 513.96M | 401.45M | 402.78M | 435.20M | 458.96M | 491.88M | 509.56M | (174.78M) | 192.50M | 218.51M | N/A | N/A |
| Return on Equity | -0.11 | -0.09 | -0.09 | -0.06 | -0.08 | -0.04 | -0.03 | N/A | -0.06 | -0.06 | N/A | N/A |
BCAX News
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO Transcript
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
Bicara Stock Is Up 50%, and One Biotech Investor Has Made It a 29% Portfolio Bet
Bicara Therapeutics Touts Cancer Drug Progress Ahead of 2026 Pivotal Data
Bicara Therapeutics Inc. (BCAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Bicara Therapeutics Inc. (BCAX) Q1 2026 Earnings Call Transcript
Bicara Therapeutics Q1 Earnings Call Highlights
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update